Skip to content

Extensive Stage Small Cell Lung Cancer Combination Treatment

Search Clinical Trials

Trial Objectives

Extensive stage small cell lung cancer (ES-SCLC) is an aggressive type of cancer that can rapidly spread to other areas of the body. This type of cancer currently has limited treatment options. The purpose of this study is to determine the efficacy and safety of lurbinectedin (a type of chemotherapy) when combined with atezolizumab (an immunotherapy treatment) as a maintenance treatment for those with ES-SCLC. This combination treatment will be compared a treatment of atezolizumab alone. Participants will be randomly chosen to receive a combination of lurbinectedin and atezolizumab or atezolizumab alone. They will not know which treatment they are receiving. The treatments are delivered by IV infusion. Participants also may be asked to provide blood samples and have a physical exam.

Who Can Participate

Individuals who are being treated at National Jewish Health with confirmed extensive-stage small-cell lung cancer (ES-SCLC) who have not yet started treatment.

Age: 18+ Gender: Any

Estimated Time Commitment

Two or more years

Payment & Reimbursement

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Jami Henriksen

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Hoffmann-La Roche

Principal Investigators

Laurie L. Carr

Laurie L. Carr, MD

Request more Information

By completing this form, you agree to learn more about this study and see if you qualify.

I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health required